Candel Therapeutics Inc (NASDAQ: CADL) is -23.50% lower on its value in year-to-date trading and has touched a low of $1.16 and a high of $14.60 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CADL stock was last observed hovering at around $6.70 in the last trading session, with the day’s loss setting it -0.06%.
Currently trading at $6.64, the stock is -13.76% and -0.38% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.89 million and changing -0.90% at the moment leaves the stock -1.17% off its SMA200. CADL registered 451.04% gain for a year compared to 6-month gain of 7.62%. The firm has a 50-day simple moving average (SMA 50) of $6.6184 and a 200-day simple moving average (SMA200) of $6.7221.
The stock witnessed a -27.59% loss in the last 1 month and extending the period to 3 months gives it a 18.57%, and is -2.92% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.30% over the week and 9.74% over the month.
Candel Therapeutics Inc (CADL) has around 42 employees, a market worth around $295.32M and $0.00M in sales. Distance from 52-week low is 472.41% and -54.52% from its 52-week high.
The EPS is expected to shrink by -21.37% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
74.0 institutions hold shares in Candel Therapeutics Inc (CADL), with institutional investors hold 32.37% of the company’s shares. The shares outstanding are 44.48M, and float is at 32.34M with Short Float at 9.04%. Institutions hold 22.53% of the Float.
The top institutional shareholder in the company is NORTHPOND VENTURES, LLC with over 1.94 million shares valued at $12.0 million. The investor’s holdings represent 6.628 of the CADL Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 0.82 million shares valued at $5.1 million to account for 2.819 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 0.82 million shares representing 2.8035 and valued at over $5.08 million, while STATE STREET CORP holds 1.6193 of the shares totaling 0.47 million with a market value of $2.93 million.
Candel Therapeutics Inc (CADL) Insider Activity
The most recent transaction is an insider sale by Barone Francesca, the company’s Chief Scientific Officer. SEC filings show that Barone Francesca sold 13,534 shares of the company’s common stock on Jan 15 ’25 at a price of $7.22 per share for a total of $97783.0. Following the sale, the insider now owns 0.11 million shares.
Candel Therapeutics Inc disclosed in a document filed with the SEC on Jan 15 ’25 that Tyagarajan Seshu (Chief Technology Officer) sold a total of 14,322 shares of the company’s common stock. The trade occurred on Jan 15 ’25 and was made at $7.22 per share for $0.1 million. Following the transaction, the insider now directly holds 96790.0 shares of the CADL stock.
Still, SEC filings show that on Jan 15 ’25, Schoch Charles disposed off 9,511 shares at an average price of $7.22 for $68717.0. The insider now directly holds 43,038 shares of Candel Therapeutics Inc (CADL).
